We are preparing the requested document. Please wait, this may take a while...!
|Application / Reactivity||Human|
|Dot Blot (DB)||2 Antibodies|
|Enzyme Immunoassay (EIA)||29 Antibodies|
|Flow Cytometry (FACS)||26 Antibodies|
|Immunoassay (IA)||4 Antibodies|
|Immunocytochemistry (ICC)||5 Antibodies|
|Immunodiffusion (ID)||12 Antibodies|
|Immunoelectrophoresis (IEP)||1 Antibodies|
|Immunofluorescence (IF)||7 Antibodies|
|Immunofluorescence (Paraffin-embedded Sections) (IF (p))||33 Antibodies|
|Immunohistochemistry (IHC)||15 Antibodies|
|Immunohistochemistry (Frozen Sections) (IHC (fro))||36 Antibodies|
|Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))||28 Antibodies|
|Immunoprecipitation (IP)||16 Antibodies|
|Immunoturbidimetry (IT)||1 Antibodies|
|Labeling (Lbl)||1 Antibodies|
|Radial Immunodiffusion (RID)||1 Antibodies|
|Radioimmunoassay (RIA)||4 Antibodies|
|Antigen||Complement Component 3 (C3) Antibodies|
|Conjugate||This C3 antibody is un-conjugated Alternatives|
Enzyme Immunoassay (EIA), Western Blotting (WB)
|2 references available|
|Supplier||Log in to see|
Product Details anti-C3 AntibodyTarget Details C3 Application Details Handling References for anti-C3 Antibody (ABIN181105) Images
|Specificity||This antibody recognises 9 kDa complement component 3a (C3a) which is present in the blood serum. The antibody shows minimal reactivity with other complement proteins in radioimmunoassays and haemagglutination.|
|Characteristics||Synonyms: CPAMD1, Complement component 3, C3 and PZP-like alpha-2-macroglobulindomain-containing protein 1|
|Purification||Affinity Chromatography on Protein A|
|Immunogen||Native purified Human C3a. Genename: C3a|
Target Details C3Product Details anti-C3 Antibody Application Details Handling References for anti-C3 Antibody (ABIN181105) Images back to top
|Alternative Name||Complement C3 (C3 Antibody Abstract)|
|Background||C3a is generated over the course of complement activation where complement 3 (C3) convertases cleave C3 to C3a and C3b, which is further degraded into iC3b and C3dg/C3d. C3 is crucial in the induction of tolerance generated when an antigen is introduced into immunoprivileged sites and this is exploited by pathogens and cancer cells to evade the immune system by inhibiting complement activation. C3a mediates local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes. C3a is expressed at significantly higher levels in colorectal cancer.Synonyms: C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1, CPAMD1, Complement component 3|
|Research Area||Complement Factors|
Application DetailsProduct Details anti-C3 Antibody Target Details C3 Handling References for anti-C3 Antibody (ABIN181105) Images back to top
Western BLot. ELISA: 1/1500-1/6000.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
|Restrictions||For Research Use only|
HandlingProduct Details anti-C3 Antibody Target Details C3 Application Details References for anti-C3 Antibody (ABIN181105) Images back to top
|Buffer||Borate buffered saline, pH 8.2 containing 0.09 % Sodium Azide as preservative|
|Precaution of Use||This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.|
|Storage||4 °C/-20 °C|
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer. Avoid repeated freezing and thawing.
Shelf life: one year from despatch.
|Expiry Date||12 months|
References for anti-C3 Antibody (ABIN181105)Product Details anti-C3 Antibody Target Details C3 Application Details Handling Images back to top
Habermann, Roblick, Luke et al.: "Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors." in: Gastroenterology, Vol. 131, Issue 4, pp. 1020-9; quiz 1284, 2006 (PubMed).
Hugli: "Human anaphylatoxin (C3a) from the third component of complement. Primary structure." in: The Journal of biological chemistry, Vol. 250, Issue 21, pp. 8293-301, 1976 (PubMed).